AMR: IMI’s Enable project reaches endpoints

  29 January 2020

The IMI project was recently granted a one-year extension to promote further progression of ongoing programmes, while keeping within the original budget of about €100m. ENABLE was formed in 2014 to accelerate the development of new antibiotics for the treatment of difficult-to-treat Gram-negative  infections. The project has so far identified five antibacterial leads.

Further reading: European Biotechnology
Author(s): TG
Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Evotec

JSS University

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS





Technology Database

Display your AMR Technology, Product and Service

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!